Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:DMKNASDAQ:PHIONASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.39-0.3%$0.38$0.30▼$3.33$9.08M-1.37167,326 shs152,811 shsDMKDMK Pharmaceuticals$0.17$0.18▼$21.70$2.34M1.111.16 million shs24.16 million shsPHIOPhio Pharmaceuticals$2.04+2.0%$1.78$0.97▼$9.79$9.79M0.992.39 million shs204,456 shsTLPHTalphera$0.49-0.7%$0.52$0.45▼$1.19$10.03M-0.1572,203 shs26,200 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-0.34%-2.89%-7.93%-45.50%-84.53%DMKDMK Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals+2.00%+10.87%+3.03%+43.66%-69.73%TLPHTalphera-0.69%-2.98%+0.62%-12.60%-52.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.2779 of 5 stars3.53.00.00.02.71.70.0DMKDMK PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.905 of 5 stars3.52.00.00.02.72.51.3TLPHTalphera2.16 of 5 stars3.82.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,968.79% UpsideDMKDMK Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$4.0096.08% UpsideTLPHTalphera 3.50Strong Buy$5.00922.49% UpsideCurrent Analyst Ratings BreakdownLatest DMK, PHIO, ACXP, and TLPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/1/2025TLPHTalpheraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/ADMKDMK Pharmaceuticals$3.62M0.00N/AN/A($0.38) per share0.00PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ATLPHTalphera$27K371.33N/AN/A$0.83 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)DMKDMK Pharmaceuticals-$26.48MN/A0.00N/AN/A-630.85%N/A-251.02%N/APHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.54N/AN/A-134.57%-108.39%8/13/2025 (Estimated)TLPHTalphera-$18.40M-$0.45N/AN/AN/AN/A-118.46%-65.82%8/12/2025 (Estimated)Latest DMK, PHIO, ACXP, and TLPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A3/31/2025Q4 2024TLPHTalphera-$0.21-$0.07+$0.14-$0.07N/AN/A3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ADMKDMK PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80DMKDMK PharmaceuticalsN/A0.580.54PHIOPhio PharmaceuticalsN/A6.386.38TLPHTalpheraN/A4.424.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%DMKDMK Pharmaceuticals38.55%PHIOPhio Pharmaceuticals57.31%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals29.60%DMKDMK Pharmaceuticals5.90%PHIOPhio Pharmaceuticals0.59%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableDMKDMK Pharmaceuticals1110.10 million9.51 millionNo DataPHIOPhio Pharmaceuticals104.80 million6.85 millionNot OptionableTLPHTalphera1920.50 million16.48 millionOptionableDMK, PHIO, ACXP, and TLPH HeadlinesRecent News About These CompaniesTalphera (NASDAQ:TLPH) Stock Price Up 0.4% - Here's WhyMay 24, 2025 | americanbankingnews.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025May 7, 2025 | prnewswire.comAll You Need to Know About Talphera (TLPH) Rating Upgrade to Strong BuyMay 7, 2025 | msn.comTalphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?April 5, 2025 | msn.comTalphera reports Q4 EPS (7c) vs. (25c) last yearApril 1, 2025 | markets.businessinsider.comTalphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comTalphera announces agreement with FDA to reduce NEPHRO CRRT study sizeApril 1, 2025 | markets.businessinsider.comTalphera Reports 2024 Financial Results and Study UpdateMarch 31, 2025 | tipranks.comTalphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of NiyadMarch 31, 2025 | msn.comTalphera, Inc. (TLPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionMarch 31, 2025 | prnewswire.com7TLPH : Earnings Outlook For TalpheraMarch 28, 2025 | benzinga.comTalphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025March 26, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMK, PHIO, ACXP, and TLPH Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.39 0.00 (-0.34%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$0.39 +0.00 (+0.08%) As of 05/29/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.DMK Pharmaceuticals NASDAQ:DMKDMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Phio Pharmaceuticals NASDAQ:PHIO$2.04 +0.04 (+2.00%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.01 -0.03 (-1.47%) As of 05/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Talphera NASDAQ:TLPH$0.49 0.00 (-0.69%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$0.50 +0.01 (+1.43%) As of 05/29/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
